Vireo Growth (VREOF) Income from Non-Controlling Interests (2025 - 2026)
Vireo Growth (VREOF) posted Income from Non-Controlling Interests of $3.6 million for Q1 2026, little changed sequentially from $3.6 million in Q1 2025, and little changed YoY from $3.6 million in Q1 2025.
Vireo Growth (VREOF) Income from Non-Controlling Interests (2025 - 2026) Analysis & Trends
Vireo Growth has reported Income from Non-Controlling Interests for 2 years, with the latest figure at $3.6 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Vireo Growth | 493.25 Mn | 350.95 Mn | 95.30 Mn | 2.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.60 Mn |
| Mar 31, 2025 | 3.60 Mn |